Proteome

Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions

Retrieved on: 
Mittwoch, Mai 8, 2024
STAC, Seer, CCO, Health, University Hospital Bonn, Proteomics, Research, Workflow, Proteome, Disease, Life, Automation, Biology, Mass spectrometry, Drug development

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced the launch of the Seer Technology Access Center (STAC) in Bonn, Germany, providing the European biopharma and life sciences communities with service programs and the latest mass spectrometry technologies to optimize deep, unbiased proteomic studies. The new facility, opening in June, will be located at Life & Brain GmbH, an independent commercial technology provider, on the campus of the University Hospital Bonn. In June 2023, Seer established the first Seer Technology Access Center at the company’s headquarters in Redwood City, California.

Key Points: 
  • The new facility, opening in June, will be located at Life & Brain GmbH, an independent commercial technology provider, on the campus of the University Hospital Bonn.
  • In June 2023, Seer established the first Seer Technology Access Center at the company’s headquarters in Redwood City, California.
  • The Seer Technology Access Center in Europe will help address an unmet need for researchers who want to conduct deep, unbiased proteomics studies to accelerate biomarker discovery and drug development.
  • To learn more about Seer’s Technology Access Center, contact your local Seer representative by requesting a consultation at www.seer.bio .

Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome

Retrieved on: 
Dienstag, Mai 7, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Doctor of Philosophy, Protein, Flagship Pioneering, Viral, Machine learning, Proteome, Entrepreneurship, Disease, Physiology, Virus, Database, MBA, Strategy, Vaccine

Flagship Pioneering, the bioplatform innovation company, today unveiled Prologue Medicines, a company unlocking the therapeutic potential of the viral proteome for the creation of powerful new medicines.

Key Points: 
  • Flagship Pioneering, the bioplatform innovation company, today unveiled Prologue Medicines, a company unlocking the therapeutic potential of the viral proteome for the creation of powerful new medicines.
  • "We asked, what if we could expand beyond the functional boundaries of the human proteome by harnessing viral evolution,” said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of the Strategic Oversight Board of Prologue.
  • “By exploring the viral proteome, we can discover novel proteins with enhanced or completely unique therapeutic properties to develop medicines for optimal patient outcomes.”
    Prologue is unlocking viral proteome-assisted drug discovery with its novel DELVE Platform.
  • “The viral proteome dwarfs the human proteome by orders of magnitude, enabling us to reveal a trove of powerful new proteins that can be used as medicines across nearly any therapeutic area,” said Lovisa Afzelius, Ph.D., MBA, Co-Founder and CEO of Prologue and Origination Partner at Flagship Pioneering.

Pixelgen Technologies Appoints Mostafa Ronaghi to Scientific Advisory Board

Retrieved on: 
Dienstag, April 30, 2024
Stanford University, Membrane, Karolinska Institute, Genomics, Mostafa Ronaghi, Pyrosequencing, Pixelation, Clear Labs, Proteome, Imperial College London, Culture, GRAIL, Drug development, Management

STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.
  • "Mostafa is a recognized life sciences visionary leader, with deep expertise in genomics and a tested entrepreneurial spirit," said Pixelgen CEO Simon Fredriksson.
  • "These attributes align well with Pixelgen's mission and culture, and we are honored to have him on our board.
  • "I'm thrilled to join Pixelgen's Scientific Advisory Board and look forward to working with the company's impressive team to continue developing Molecular Pixelation," Ronaghi said.

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

Retrieved on: 
Dienstag, April 9, 2024
Lung cancer, Survival, NSCLC, Immunotherapy, Colorectal cancer, Central nervous system, Patient, CNS, Neoplasm, AACR, PDX, Clinical trial, Pancreatic cancer, Cancer, CRC, Metastasis, Proteome, PD-1, Pharmaceutical industry

- The Phase 1/2 PROSPER clinical trial is currently evaluating FMC-376 in patients with KRASG12C cancers, regardless of prior KRAS inhibitor therapy BOSTON and SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today presented new preclinical data on its KRASG12C inhibitor, FMC-376, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. The new findings demonstrate FMC-376’s potential to overcome known mechanisms of innate and acquired resistance and in a CNS model of metastasis as a monotherapy and increase the efficacy of PD-1 immunotherapy in combination.

Key Points: 
  • “These data demonstrate FMC-376’s unmatched potential to overcome over 90 percent of known resistance mechanisms, including those cancers that have become refractory to approved KRAS inhibitors.
  • The differentiated dual direct mechanism of action of FMC-376 offers the potential to overcome the resistance and lack of response seen with current KRASG12C single-acting treatments.
  • These results reinforce that FMC-376 has the potential to overcome limitations of single-acting KRASG12C inhibitors.
  • The combination of FMC-376 with an immune checkpoint inhibitor also leads to an increased response and survival in preclinical models.

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Donnerstag, April 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.

Key Points: 
  • This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “We are excited to join forces with Alamar to advance proteomics research.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Dienstag, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

Atomwise Publishes Results from 318-Target Study Showcasing AtomNet AI Platform’s Ability to Discover Structurally Novel Chemical Matter

Retrieved on: 
Dienstag, April 2, 2024
Research, Technology, Neurology, Health Technology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Artificial Intelligence, AIMS, Biochemistry, Disease, Executive, University, HTS, Patient, AI, Scientific Reports, OTUD7B, IND, PPM1D, Biology, Biophysics, Cancer, Pharmacokinetics, TYK2, Development, Probability, Artificial intelligence, Proteome, Pharmaceutical industry

Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.

Key Points: 
  • Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.
  • AtomNet also showed a remarkable ability to discover novel chemical matter, averaging over seven structurally distinct bioactive compounds per target.
  • Developed by Atomwise, AtomNet was the first deep neural network designed to predict the bioactivity of small molecules in structure-based drug discovery.
  • Our belief is structurally novel chemical matter increases the likelihood of developing first-in-class and best-in-class medicines that have the potential to transform patient care.

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Donnerstag, April 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.

Key Points: 
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: "We are excited to join forces with Alamar to advance proteomics research.
  • This partnership underscores the commitment of both companies to scientific excellence and their shared vision of advancing precision medicine through innovative technologies.

Integral Molecular Achieves ISO 9001 Certification for its Membrane Proteome Array Service

Retrieved on: 
Mittwoch, März 27, 2024
Certification, Culture, Biotechnology, NDA, Integral, MPA, QMS, Antibody, IS0, Drug development, Safety, Therapy, ISO, Collection, FDA, BLA, Proteome

PHILADELPHIA, March 27, 2024 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery and characterization, proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ (MPA) specificity testing services. This platform is a vital tool for biotechnology and pharmaceutical companies to assess the safety and off-target reactivity of therapeutic antibodies and other biologics.

Key Points: 
  • ISO 9001 certification validates Integral Molecular's quality processes for its Membrane Proteome Array, reflecting the company's commitment to quality.
  • PHILADELPHIA, March 27, 2024 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery and characterization, proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ (MPA) specificity testing services.
  • "Integral Molecular has maintained a culture of commitment to delivering exceptional quality products and services for over 20 years.
  • As the industry increasingly relies on MPA specificity profiling to support drug safety, we are delighted to receive ISO 9001 Certification to reinforce our commitment to quality for our customers."

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Mittwoch, März 6, 2024
Proteome, NCT, Safety, Pharmacokinetics, AACR, Pharmaceutical industry

BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced new preclinical data for FMC-376, a first-in-class direct dual inhibitor of ON+OFF KRASG12C currently being explored in a Phase 1/2 trial, will be shared at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced new preclinical data for FMC-376, a first-in-class direct dual inhibitor of ON+OFF KRASG12C currently being explored in a Phase 1/2 trial, will be shared at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.
  • FMC-376 was discovered by applying the Frontier™ Platform to directly engage both ON+OFF KRASG12C with exquisite selectivity.
  • The differentiated dual direct mechanism of action of FMC-376 offers the potential to overcome the lack of response and resistance seen with current KRASG12C single-acting treatments.
  • For more information on the PROSPER trial, please visit clinicaltrials.gov .